Quad vs. Glute vs. Deltoid: What TRT Clinics Actually Recommend for Testosterone Cypionate Injections

The short answer: glute (ventrogluteal) and quad (vastus lateralis) are both solid sites for testosterone cypionate self-injection, and most TRT clinics now teach one or both. The deltoid is increasingly discouraged for oil-based depots — and there's a documented reason why.

Why Injection Site Matters More Than You Might Think

Testosterone cypionate (Depo-Testosterone) is an oil-based depot that needs to land deep in a large, well-perfused muscle to release predictably. The FDA label specifies "deep in the gluteal muscle," and the Endocrine Society Clinical Practice Guidelines on male hypogonadism reinforce intramuscular administration as the standard for long-acting esters. Needle length matters: most men need 1–1.5 inches to clear subcutaneous fat and reach true muscle tissue. Miss the muscle and you get an unintended subQ depot — slower, lumpier absorption and more local irritation [1].

Modern TRT clinics have quietly shifted away from the traditional dorsogluteal (upper-outer buttock) site toward the ventrogluteal region — the lateral hip area bounded by the greater trochanter, anterior superior iliac spine, and iliac crest. Anatomical analyses show the ventrogluteal site sits roughly twice as far from the superior gluteal artery and sciatic nerve as the dorsogluteal zone [4]. That margin matters when you're injecting twice weekly for years. For clinics that prescribe weekly or twice-weekly 50–75 mg doses — the protocol most consistent with the Bhasin et al. 2018 NEJM Testosterone Trials data on maintaining mid-normal serum levels — patient safety over thousands of injections is a real design consideration.

If you're comparing your delivery options, our hormone optimization treatment guide breaks down injectables alongside topical and nasal alternatives like Natesto.

Quad (Vastus Lateralis): The Self-Injection Workhorse

The anterolateral thigh is now the most common self-injection site taught by TRT clinics, and the anatomy supports the preference. The outer middle third of the thigh — divide hip to knee into thirds, use the middle outer section — keeps the needle well clear of the femoral artery and femoral nerve branches that run medially [3]. A 1-inch, 23–25g needle works for most men; go to 1.5 inches if body fat is higher.

Patients generally find the thigh easier to visualize and reach alone, without a partner or mirror. The trade-off: some men experience more post-injection soreness here than in the glute, particularly if the muscle is tense during injection. Sitting with a slight knee bend relaxes the vastus lateralis enough to reduce this. Rotating left and right thigh on alternate injections — or alternating thigh and glute — prevents the scar tissue buildup that comes with hitting the same spot repeatedly [1].

For a detailed technique walkthrough, see our practical guide to testosterone cypionate injection sites.

Why the Deltoid Is Falling Out of Favor

The deltoid gets recommended in informal guides because it's easy to access and familiar from vaccine injections. For low-volume medications, that logic holds. For testosterone cypionate, it increasingly doesn't. A case report documented recurrent localized rhabdomyolysis in a patient who had tolerated thigh and glute injections without incident, then developed serious muscle injury after switching to deltoid injections [4]. The proposed mechanism: the deltoid is simply too small to safely buffer a concentrated oil depot at typical TRT volumes (0.5–1 mL), creating a high drug-per-gram-of-muscle ratio that can trigger necrosis.

Several expert reviews now explicitly advise against deltoid intramuscular injections for oil-based testosterone. If you're on a program through a provider like Marek Health, their protocols typically steer patients toward ventrogluteal or vastus lateralis sites for this reason. The deltoid remains acceptable for lower-volume aqueous injections — vaccines, some peptides — but not as a routine site for cypionate. Also worth noting: if you're considering alternatives that sidestep injection site decisions entirely, topical gels like AndroGel or Testim, or nasal Natesto, are worth discussing with your prescriber, though each has its own absorption and transfer tradeoffs. Our comparison of AndroGel vs. Testim absorption covers that in detail.

The JCEM has published multiple analyses reinforcing that consistent intramuscular deposition — not any specific muscle — is what drives stable serum testosterone and predictable hematocrit response. Site-switching mid-protocol without adjusting dose is one underappreciated cause of erratic lab values [5].

---

Frequently asked questions

Which injection site is safest for testosterone cypionate self-injection?

The ventrogluteal and vastus lateralis (outer thigh) sites are the safest for self-administered testosterone cypionate, based on anatomical distance from major nerves and vessels and the ability to reliably reach deep muscle tissue [4]. The ventrogluteal region offers the largest safety margin from the sciatic nerve, while the vastus lateralis is the easiest site to visualize and self-inject without assistance. Both are preferable to the dorsogluteal site for most self-injecting patients.

How often should injection sites be rotated on TRT?

Most TRT clinics recommend rotating injection sites with every injection — for example, alternating right and left thigh, or cycling between thigh and glute — to prevent scar tissue accumulation and maintain consistent absorption [1]. Repeated injections into the same precise spot can create fibrotic tissue over time, which slows drug release and increases local discomfort. Many twice-weekly protocols use a four-point rotation: right thigh, left thigh, right ventrogluteal, left ventrogluteal.

Can testosterone cypionate be injected subcutaneously instead of intramuscularly?

Subcutaneous testosterone injection is used off-label and is not approved under the Depo-Testosterone label, which spec